Search Results - "Obrocea, M M"

The novel, telomerase-directed, telomere-targeted, anticancer agent 6-thio-dG (THIO) demonstrates potent activity and induces antitumor immunity in hepatocellular carcinoma (HCC) models by Shay, J., Mender, I., Siteni, S., Obrocea, M., Vitoc, V., Gryaznov, S.

Get full text

1193TiP A phase II, multicenter, open-label, dose-finding study evaluating THIO sequenced with cemiplimab in patients with advanced NSCLC by Ciuleanu, T-E., Joshi, R., Gryaznov, S., Vitoc, V., Obrocea, M.

Get full text

1493P A phase II, multi-center, open-label, dose-optimization study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Preliminary results by Jankowski, T., Sótér, S., Raumlau, R., Chilingirova, N., Cholakova, M.D., Seidl, B., Moore, M., Joshi, R., Vitoc, V., Zaporojan, V., Gryaznov, S., Watkins, P., Obrocea, M.

Get full text

In vitro carboplatin-mesna interaction in aqueous solution, human plasma and urine by Obrocea, M M, Nassim, M A, Molepo, M J, Shirazi, F H, Gallant, G, Dulude, H, Vincent, M D, Stewart, D J, Goel, R

“…The chemotherapeutic benefit of synergistic drug combinations and higher drug dosages has generated interest in the application of these regimens to cancer…”
Get more information

A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors by WEBER, Jeffrey S, VOGELZANG, Nicholas J, OBROCEA, Mihail, BOT, Adrian, ERNSTOFF, Marc S, GOODMAN, Oscar B, CRANMER, Lee D, MARSHALL, John L, MILES, Sabrina, ROSARIO, Dar, DIAMOND, David C, ZHIYONG QIU

“…Preferentially expressed antigen in melanoma (PRAME) and prostate-specific membrane antigen (PSMA) are tumor-associated antigens implicated in cellular…”
Get full text

Phase 1 Trial of Intranodal Injection of a Melan-A/MART-1 DNA Plasmid Vaccine in Patients With Stage IV Melanoma by WEBER, Jeffrey, BOSWELL, William, BOT, Adrian, SMITH, John, HERSH, Evan, SNIVELY, Jolie, DIAZ, Mella, MILES, Sabrina, XIDING LIU, OBROCEA, Mihail, ZHIYONG QIU

“…Nineteen patients with stage IV melanoma were treated in an escalating dose, phase 1 trial of a DNA plasmid vaccine pSEM. The plasmid encoded T-cell epitopes…”
Get full text

A phase I trial of intra-lymph-node administration of a novel immunotherapeutic regimen (MKC1106-MT) in patients with advanced melanoma by Weber, J. S., Ribas, A., Bot, A., Obrocea, M., Chmielowski, B., Rosario, D., Qiu, Z., Comin-Anduix, B.

“…Abstract only…”
Get full text

Pharmacokinetics of gimatecan, and orally administered camptothecin analogue, in patients with malignant gliomas by Supko, J. G., Alderson, L., Wen, P., Cassidy, K., Pace, S., Obrocea, M., Hochberg, F.

“…Abstract only…”
Get full text

Pharmacokinetics of gimatecan, and orally administered camptothecin analogue, in patients with malignant gliomas by Supko, J. G., Alderson, L., Wen, P., Cassidy, K., Pace, S., Obrocea, M., Hochberg, F.

“…Abstract only…”
Get full text

An HPLC method for the measurement of 5-fluorouracil in human plasma with a low detection limit and a high extraction yield by Nassim, Mark Adel, Shirazi, Farshad H, Cripps, Christine M, Veerasinghan, Shereeni, Molepo, Matshela J, Obrocea, Mihail, Redmond, Diedre, Bates, Susan, Fry, Diane, Stewart, David J, Goel, Rakesh

“…High performance liquid chromatographic (HPLC) techniques for the quantification of 5-fluorouracil (5-FU) in human plasma have been reported in the literature,…”
Get more information

Effects of PALA on the pharmacokinetics of 5-fluorouracil by Nassim, M A, Rouini, M R, Cripps, M C, Shirazi, F H, Veerasinghan, S, Molepo, J M, Obrocea, M, Redmond, D, Bates, S, Fry, D, Stewart, D J, Goel, R

“…N-(phosphonacetyl)-L-aspartate (PALA) modulates the activity of 5-fluorouracil (5-FU) by inhibiting pyrimidine biosynthesis. A cross-over study was conducted…”
Get more information